Federal contract award
N3239822P0313
DEVELOPMENT OF DENGUE VIRUS TETRAVALENT NS1 AND E VACCINE USING THE HERPES SIMPLEX VIRUS DELTA-G(GJDI)-2 VECTOR.
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Defense |
| Office | NAVAL MEDICAL RESEARCH CENTER |
| NAICS | 541715 — Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) |
| PSC | AN25 — HEALTH R&D SERVICES; HEALTH RESEARCH AND TRAINING; EXPENSES FOR R&D FACILITIES AND MAJOR EQUIPMENT |
| Parent award / vehicle | Not reported |
| Set-aside | NO SET ASIDE USED. |
| Pricing type | FIRM FIXED PRICE |
| Obligations | $168.0K |
| Current contract value | $168.0K |
| Potential contract value / ceiling | $168.0K |
| Start date | Sep 27, 2022 |
| Current end date | Sep 27, 2023 |
| Potential end date | Sep 27, 2023 |
| Latest award activity | Sep 27, 2022 |
| Source loaded | Sep 26, 2026 |
Funding and modification history
Showing the latest 1 of 1 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| Sep 27, 2022 | 0 | $168.0K | DEVELOPMENT OF DENGUE VIRUS TETRAVALENT NS1 AND E VACCINE USING THE HERPES SIMPLEX VIRUS DELTA-G(GJDI)-2 VECTOR. |
Research next steps
- Check the stated set-aside against the solicitation and current certifications.
- Review the award scope and buyer evidence before making a bid/no-bid decision.